Alector vs Keros Therapeutics
Keros Therapeutics is the larger business, with $244m of revenue in fiscal 2025 against $21.0m for Alector (11.6 times as much). Keros Therapeutics grew faster (6769.4% against -79.1%). Keros Therapeutics kept more of each dollar of sales as profit: a net margin of 35.7% against -679.2%. Keros Therapeutics carries less debt relative to equity (0.0% against 33.8%).
| Latest fiscal year | AlectorALEC, 2025 | Keros TherapeuticsKROS, 2025 |
|---|---|---|
| Revenue | $21.0m | $244m |
| Revenue growth | -79.1% | 6769.4% |
| Net income | −$143m | $87.0m |
| Operating margin | -741.3% | 27.7% |
| Net margin | -679.2% | 35.7% |
| Return on equity | -181.6% | 19.9% |
| Free cash flow | −$184m | $106m |
| Cash | $65.8m | $287m |
| Total debt | $10.4m | $0 |
| Debt to equity | 33.8% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $375m |
| Employees | 103 | 78 |
| Market value | $229m | $215m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 21 sales | 6 buys, 12 sales |